Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

David S. Hong,Nicole Concin,Ignace Vergote,Johann S. de Bono,Brian M. Slomovitz,Yvette Drew,Hendrik-Tobias Arkenau,Jean-Pascal Machiels,James F. Spicer,Robert Jones,Martin D. Forster,Nathalie Cornez,Christine Gennigens,Melissa L. Johnson,Fiona C. Thistlethwaite,Reshma A. Rangwala,Srinivas Ghatta,Kristian Windfeld,Jeffrey R. Harris,Ulrik Niels Lassen,Robert L. Coleman

DOI: https://doi.org/10.1158/1078-0432.CCR-19-2962

IF: 13.801

2020-03-14

Clinical Cancer Research

Abstract:Purpose: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623). Patients and Methods: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. Results: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab + doublet chemotherapy. Fifty-one percent of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%–37%]. Median duration of response (DOR) was 4.2 months (range: 1.0 + –9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%–43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%–35%), median DOR of 6.0 months (range: 1.0 + –9.7), and 6-month PFS rate of 40% (95% CI: 24%–55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. Conclusions: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.

oncology